EDITORIAL : Risks associated with sunitinib use and monitoring to improve patient outcomes = EDITORIAL : Risks associated with sunitinib use and monitoring to improve patient outcomes

참고문헌 (Reference)

1 Izzedine H, "VEGF signalling inhibition-induced proteinuria:mechanisms, significance and management" Eur J Cancer 46 : 439 ~ 448 -, 2010

2 Kerbel RS, "Tumor angiogenesis" N Engl J Med 358 : 2039 ~ 2049 -, 2008

3 Sivendran S, "Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis" Cancer Treat Rev 38 : 919 ~ 925, 2012

4 Tamaskar I, "Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib" Ann Oncol 19 : 265 ~ 268 -, 2008

5 Wolter P, "The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation" Br J Cancer 99 : 448 ~ 454 -, 2008

6 Motzer RJ, "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma" N Engl J Med 356 : 115 ~ 124 -, 2007

7 Wong E, "Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity" Thyroid 17 : 351 ~ 355 -, 2007

8 Gore ME, "Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial" Lancet Oncol 10 : 757 ~ 763 -, 2009

9 백선하, "Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea" The Korean Journal of Internal Medicine 29 (1) : 40 ~ 48, 2014

10 Motzer RJ, "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma" J Clin Oncol 27 : 3584 ~ 3590 -, 2009

11 Kumar R, "Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors" Br J Cancer 101 : 1717 ~ 1723 -, 2009

12 Zhou A, "Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience" Asia Pac J Clin Oncol 8 : 132 ~ 144 -, 2012

13 Mendez-Vidal MJ, "Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma" Cancer Metastasis Rev 31 (Suppl 1) : S19 ~ S27 -, 2012

14 Rini BI, "Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib" J Natl Cancer Inst 99 : 81 ~ 83 -, 2007

15 Tryggvason K, "Hereditary proteinuria syndromes and mechanisms of proteinuria" N Engl J Med 354 : 1387 ~ 1401 -, 2006

16 Lammie A, "Expression of c-kit and kit ligand proteins in normal human tissues" J Histochem Cytochem 42 : 1417 ~ 1425 -, 1994

17 Lacouture ME, "Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib" Oncologist 13 : 1001 ~ 1011 -, 2008

18 Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial" Lancet 36 : 1329 ~ 1338, 2006

19 Orphanos GS, "Cardiotoxicity induced by tyrosine kinase inhibitors" Acta Oncol 48 : 964 ~ 970 -, 2009